ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1251-1264

  Sun, X P ^a   Zhang, X ^a   He, C ^a   Qiao, H ^a   Jiang, X ^a   Jiang, H ^a   Sun, X ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

ABT 737; Apoptosis; Apoptosis inducers; Arsenic trioxide; Cell proliferation; Gastric cancer; Gastric carcinoma cell lines; MCL 1; Myeloid cell leukaemia 1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; APOPTOSIS INDUCING FACTOR; ARSENIC TRIOXIDE; PROTEIN MCL 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STOMACH CARCINOMA; TUMOR XENOGRAFT;

EID: 84867504415     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000404     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011; 61: 69 90.
2. Bozzetti F, Yu W, Baratti D, et al: Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 2008; 98: 273 - 276.
3. Lim L, Michael M, Mann GB, et al: Adjuvant therapy in gastric cancer. J Clin Oncol 2005; 23: 6220 - 6232.
4. Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126 1132.
5. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
6. Tahir SK, Yang X, Anderson MG, et al: Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176 - 1183.
7. L potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006; 66: 8731 - 8739.
8. Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375 388.
9. L/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374 - 2380.
10. Del Gaizo Moore V, Brown JR, Certo M, et al: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121. (Pubitemid 46048458)
11. Kang MH, Kang YH, Szymanska B, et al: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT737 in vitro and in vivo. Blood 2007; 110: 2057 2066.
12. van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389 - 399.
13. Vogler M, Weber K, Dinsdale D, et al: Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030 1039.
14. Wacheck V, Cejka D, Sieghart W, et al: Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther 2006; 5: 1348 - 1354.
15. Tsujitani S, Saito H, Wakatsuki T, et al: Relationship between expression of apoptosisrelated proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today 2012; 42: 225 232.
16. L inhibitor ABT-737. Oncogene 2007; 26: 3972 - 3979.
17. Yecies D, Carlson NE, Deng J, et al: Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304 - 3313.
18. Keuling AM, Felton KE, Parker AA, et al: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8dependent pathway. PLoS One 2009; 4: e6651.
19. Tagscherer KE, Fassl A, Campos B, et al: Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27: 6646 - 6656.
20. Chen S, Dai Y, Harada H, et al: Mcl-1 downregulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67: 782 - 791.
21. L inhibitor, ABT-737. Clin Cancer Res 2008; 14: 8132 - 8142.
22. Zhu J, Chen Z, Lallemand-Breitenbach V, et al: How acute promyelocyte leukaemia revived arsenic. Nat Rev Cancer 2002; 2: 705 - 713.
23. Litzow MR: Arsenic trioxide. Expert Opin Pharmacother 2008; 9: 1773 - 1785.
24. Emadi A, Gore SD: Arsenic trioxide - an old drug rediscovered. Blood Rev 2010; 24: 191 199.
25. Zheng Y, Zhou M, Ye A, et al: The conformation change of Bcl-2 is involved in arsenic trioxideinduced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World J Surg Oncol 2010; 8: 31.
26. Li Y, Qu X, Qu J, et al: Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett 2009; 284: 208 - 215.
27. Morales AA, Gutman D, Lee KP, etal: BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 2008; 111: 5152 - 5162.
28. Chen H, Sun B, Pan S, et al: Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009; 20: 131 -140.
29. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
30. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646 -674.
31. Lessene G, Czabotar PE, Colman PM: BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989 - 1000.
32. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294 - 1305.
33. Ugarenko M, Nudelman A, Rephaeli A, et al: ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol 2010; 79: 339 - 349.
34. Kutuk O, Letai A: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008; 68: 7985 - 7994.
35. Sieghart W, Losert D, Strommer S, et al: Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 2006; 44: 151 - 157.
36. Bae J, Leo CP, Hsu SY, etal: MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000; 275: 25255-25261.
37. Luo L, Qiao H, Meng F, et al: Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int J Cancer 2006; 118: 1823 1830.
38. . Zhang TC, Cao EH, Li JF, et al: Induction of apoptosis and inhibition of human gastric cancer MCG-803 cell growth by arsenic trioxide. Eur J Cancer 1999; 35: 1258 - 1263.
39. Baumgartner M, Sturlan S, Roth E, et al: Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 2004; 112: 707 - 712